2,4,6-三(苯基甲氧基)苯甲酸 | 55018-94-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,4,6-三(苯基甲氧基)苯甲酸
• 英文名称: 2,4,6-tribenzyloxybenzoic acid
• 英文别名: 2,4,6-Tris(benzyloxy)benzoic acid；2,4,6-tris(phenylmethoxy)benzoic acid
• CAS: 55018-94-5
• 化学式: C₂₈H₂₄O₅
• 分子量: 440.496
• InChiKey: BTLDQQZITORVCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,4,6-三(苯基甲氧基)苯甲酸 生成 1,3,5-三(苯基甲氧基)苯
  参考文献：
  名称：

  地衣呫吨酮的全合成：结构修订1 ，2

  摘要：

  描述了通过明确方法制备去甲己基己酮6a的几种氯化衍生物的方法。讨论了这些化合物的1 H NMR光谱，并对先前指定用于地衣chen吨的几种结构提出了质疑。表3总结了建议的修订。

  DOI：

  10.1016/0040-4020(78)80055-6

文献信息

• Acyl Hydrazines as Kinase Inhibitors, in Particular for Sgk
  申请人：Gericke Rolf

  公开号：US20080167380A1

  公开（公告）日：2008-07-10

  Novel acyl hydrazides of the formula (I), in which R 1 -R 9 have the meanings indicated in claim 1 , are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type.

  式（I）中R1-R9具有权利要求书中所示含义的新型酰肼，是SGK抑制剂，可用于治疗SGK引起的疾病和不适，如糖尿病、肥胖症、代谢综合征（血脂异常）、全身和肺动脉高压、心血管疾病和肾脏疾病，通常用于任何类型的纤维化和炎症过程。
• Acyl hydrazines as kinase inhibitors, in particular for SGK
  申请人：Merck Patent GmbH

  公开号：US07767716B2

  公开（公告）日：2010-08-03

  Novel acyl hydrazides of the formula (I), in which R1-R9 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in fibroses and inflammatory processes of any type.

  式(I)中R1-R9具有权利要求书1中指示的含义，是SGK抑制剂，可用于治疗SGK诱导的疾病和症状，如糖尿病、肥胖症、代谢综合征（血脂异常）、全身和肺动脉高压、心血管疾病和肾脏疾病，通常用于任何类型的纤维化和炎症过程。
• Anti-HIV-1 activity of a tripodal receptor that recognizes mannose oligomers
  作者：Eva Rivero-Buceta、Paula Carrero、Elena Casanova、Elisa G. Doyagüez、Andrés Madrona、Ernesto Quesada、María Jesús Peréz-Pérez、Raquel Mateos、Laura Bravo、Leen Mathys、Sam Noppen、Evgeny Kiselev、Christophe Marchand、Yves Pommier、Sandra Liekens、Jan Balzarini、María José Camarasa、Ana San-Félix

  DOI：10.1016/j.ejmech.2015.10.027

  日期：2015.12

  The glycoprotein gp120 of the HIV-1 viral envelope has a high content in mannose residues, particularly alpha-1,2-mannose oligomers. Compounds that interact with these high-mannose type glycans may disturb the interaction between gp120 and its (co)receptors and are considered potential anti-HIV agents. Previously, we demonstrated that a tripodal receptor (1), with a central scaffold of 1,3,5-triethylbenzene substituted with three 2,3,4-trihydroxybenzoyl groups, selectively recognizes alpha-1,2-mannose polysaccharides. Here we present additional studies to determine the anti-HIV-1 activity and the mechanism of antiviral activity of this compound. Our studies indicate that 1 shows anti-HIV-1 activity in the low micromolar range and has pronounced gp120 binding and HIV-1 integrase inhibitory capacity. However, gp120 binding rather than integrase inhibition seems to be the primary mechanism of antiviral activity of 1. (C) 2015 Elsevier Masson SAS. All rights reserved.
• ACYLHYCLRAZIDE ALS KINASE INHIBITOREN INSBESONDERE FÜR SGK
  申请人：Merck Patent GmbH

  公开号：EP1866280A1

  公开（公告）日：2007-12-19
• US7767716B2
  申请人：——

  公开号：US7767716B2

  公开（公告）日：2010-08-03